Angiopoietin-like Protein 3 AND Cardiovascular Disease: A Mini Review

Srinidhi Rai a*#

a Department of Biochemistry, NITTE (Deemed to be University), KS Hegde Medical Academy (KSHEMA), Mangalore-575018, India.

Author’s contribution

The sole author designed, analysed, interpreted and prepared the manuscript.

ABSTRACT

Objective of the review is to explore the role of angiopoietin like 3 protein (ANGPTL3) as a risk factor for cardiovascular disease. ANGPTL3 (human), one member of the angiopoietin-like protein (ANGPTL) family, has been identified as an important regulator of lipid metabolism. Dyslipidemia, characterized by elevation of plasma low density lipoprotein cholesterol (LDL-C), triglyceride (TG) and reduction of plasma high density lipoprotein cholesterol (HDL-C), has been verified as a causal risk factor for cardiovascular diseases (CVD), leading to a high mortality rate in general population. There may be an association between ANGPTL3, dyslipidemia, diabetes and cardiovascular risk.

Keywords: Angiopoietin -like 3; hyperlipidemia; T2DM; CVD.

1. INTRODUCTION

Angiopoietin-like protein 3 (ANGPTL3) is one of the major regulators of lipoprotein metabolism. It is specifically produced by the hepatocytes and then secreted into circulation. ANGPTL3 is regulated by liver X receptor (LXR), insulin and angiopoietin-like protein 8 (ANGPTL8) [1,2]. ANGPTL3 inhibits lipoprotein lipase as well endothelial lipase activity and therefore, increase serum triglyceride and HDL-c. Elevated plasma triacylglycerol (TG) and LDL-C levels are
independent risk factors for cardiovascular disease (CVD). There is an increase in the prevalence of diabetes being associated with the risk of Cardio vascular disease. The effect of ANGPTL3 in regulating plasma lipid metabolism and thereby contributing to the risk of CVD in diabetes is the need for the hour.

2. DM, HYPERLIPIDEMIA, CVD RISK

Cardiovascular disease is the most important cause of morbidity and mortality among patients with type 2 diabetes. Hyperglycemia, hypertension, even borderline-high-risk LDL cholesterol, and atherogenic dyslipidemia confers increased risk for CVD [3]. Over time, high blood glucose can damage the blood vessels and the nerves that control heart and blood vessels. Longer the duration of diabetes, higher the chances of developing heart disease [4]. In adults with diabetes, the most common causes of death are CVD and stroke. Risk of mortality due to CVD is double in diabetics as compared to non-diabetics [5].

3. ANGPTL3 AND INSULIN SENSITIVITY

ANGPTL3 levels are associated with insulin sensitivity and glucose metabolism [6,7]. High levels of hepatic ANGPTL3 mRNA and protein have been observed in insulin-resistant and insulin-deficient mice [7]. Insulin and ANGPTL3 may influence lipid metabolism and may predispose diabetics to a higher CVD risk.

4. ANGPTL3, LIPID PROFILE AND CARDIOVASCULAR DISEASE

ANGPTL3 is an endogenous inhibitor of lipoprotein lipase (LPL). Rare loss-of-function variants in ANGPTL3 have been shown to be associated with decreased triglyceride levels as well as decreased low-density lipoprotein (LDL) cholesterol and HDL cholesterol levels. The disturbances in lipid metabolism such as elevation of plasma LDL-C, TG and reduction of plasma HDL-C results in dyslipidemia and it is associated with CVD risk. Deficiency of ANGPTL3 is associated with hypolipidemia and reduced risk of CVD in Caucasians [8-10].

ANGPTL3 has been considered as an important and novel regulator of plasma lipids. By inhibiting Lipoprotein lipase (LPL) and endothelial lipase (EL) ANGPTL3 regulates plasma lipids. ANGPTL3 inactivation lowers LDL-C independently of the classical LDLR-mediated pathway. A study by Rene et al showed that ANGPTL3 inhibition reduces VLDL-lipid content and size, generating remnant particles that are efficiently removed from the circulation [11]. This suggests that ANGPTL3 inhibition lowers LDL-C by limiting LDL particle production.

Over-expression of ANGPTL3 and ANGPTL8 could both lead to increased serum TG levels in mice. On the contrary, in presence of loss of function mutations, the ability of ANGPTL3 to raise plasma TG levels decreased mildly [2].

Over the last few decades, tremendous progress has been made in understanding and decreasing the incidence of coronary heart disease (CHD). Low-density lipoprotein cholesterol (LDL-C) has been established as a major causal risk factor for atherosclerosis and CHD. Remarkable efforts have been made to develop LDL-lowering therapies, and statins have been proven to be an effective means of reducing the risk of CHD. However, even with the use of statin therapy, there remains a large residual risk of CHD, particularly in patients with familial hypercholesterolemia [12]. In light of these observations, an intensive search for new molecular targets to further reduce CHD risk is ongoing. Newer drug target is found to be proprotein convertase subtilisin/kexin type 9 (PCSK9) and it was confirmed to be useful with respect to the reduction of LDL-C levels in patients [13,14]. Since the efficacy of both statins and PCSK9 antibody therapies largely depends on functional LDL receptors, patients with LDL receptor deficiencies show limited responses to both therapies. In such circumstances, most appropriate promising molecular target is ANGPTL3.

ANGPTL3 is unique in that it regulates all 3 major lipid traits: LDL-C, high-density lipoprotein cholesterol (HDL-C), and triglycerides. The primary action of ANGPTL3 is to inhibit lipoprotein lipase (LPL), which hydrolyzes the triglycerides carried in triglyceride rich lipoproteins in the circulation [15]. ANGPTL3 also inhibits endothelial lipase to modulate HDL-C metabolism [16]. The mechanism by which ANGPTL3 regulates LDL-C remains unclear [17].

ANGPTL3 therapies may have the potential to reinforce the current arsenal of lipid lowering agents, particularly for high-risk populations with refractory hyperlipidemia despite advanced treatments. Therapeutic application of ANGPTL3
gene editing could be of great value as it is independent of LDL receptor status. The aim of this article is to suggest gene editing of ANGPTL3 would be beneficial in reducing CVD risk by lowering lipid levels in mice models.

ANGPTL family of proteins have an important role in lipid management, especially with respect to triglyceride metabolism, in patients with diabetes [18]. Studies have suggested that selective targeting of ANGPTL3 is useful in the treatment of conditions like familial partial lipodystrophy [18-22].

5. FUTURE RESEARCH PERSPECTIVES

A research study may be planned to find the association between mutations of ANGPTL3 and risk of CVD. This may emphasize the role of ANGPTL3 in predisposing diabetic patients to an added risk of CVD. Effectiveness of gene silencing of ANGPTL3 in reducing lipid levels may be of great help in combating dyslipidemia of diabetes mellitus. There are no studies to the best of our knowledge which have combined human and animal experiments in a complementary manner as proposed.

6. CONCLUSION

The study may acknowledge the important public health message of risk factor modification, in particular lipid lowering, for the prevention of CHD. The study emphasizes on the secondary prevention of CHD by focusing on the role of lipid lowering at the genetic level (that is, the treatment of low density lipoprotein (LDL) cholesterol) in delaying the progression of the clinical and angiographic findings in patients with clinically manifest CHD especially in diabetics. It is also importantly emphasizes that the unmet need for prevention and suitable treatment for diabetic and dislipidemic patients is likely to grow (with increasing numbers of such patients in the everyday clinical practice). Additionally, because of the paucity of data and lack of well-designed studies that answer the questions on the efficacy, safety, and cost-effectiveness of long-term interventions to reduce LDL-C in high-risk populations.

CONSENT

It is not applicable.

ETHICAL APPROVAL

It is not applicable.

COMPETING INTERESTS

Author has declared that no competing interests exist.

REFERENCES

1. Inaba T, Matsuda M, Shimamura M, Takei N, Terasaka N, Ando Y, Yasumo H, Koishi R, Makishima M, Shimomura I. Angiopoietin-like protein 3 mediates hypertriglyceridemia induced by the liver X receptor. J Biol Chem. 2003;278(24):21344–51.
2. Quagliarini F, Wang Y, Kozlitina J, Grishin NV, Hyde R, Boerwinkle E, Valenzuela DM, Murphy AJ, Cohen JC, Hobbs HH. Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci USA. 2012;109(48):19751–6.
3. Scott M, Grundy, Ivor J, Benjamin, et al., Diabetes and Cardiovascular Disease; A statement for Healthcare Professionals From the American Heart Association; Circulation. 1999;100:1134–1146
4. Huo X, Gao L, Guo L, et al. Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type 2 diabetes in China: a cross-sectional study. The Lancet Diabetes & Endocrinology. 2016;4(2):115–124.
5. National Centers for Disease Control and Prevention. National Diabetes Statistics Report; 2014. Accessed December 22, 2016.
6. Robciuc MR, et al. Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids. Arterioscler Tromb Vasc Biol. 2013;33:1706–1713.
7. Inukai, K. et al. ANGPTL3 is increased in both insulin-deficient and -resistant diabetic states. Biochem Biophys Res Commun. 2004;317:1075–1079.
8. Stitzel, N. O. et al. ANGPTL3 Deficiency and Protection against Coronary Artery Disease. J Am Coll Cardiol. 2017;69:2054–2063.
9. Romeo S, et al. Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J Clin Invest. 2009;119:70–79.
10. Dewey FE, et al. Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. N Engl J Med. 2017;377:211–221.
11. Adam RC, Mintah IJ, Alexa-Braun CA, Shihanian LM, Lee JS, Banerjee P, Hamon SC, Kim HI, Cohen JC, Hobbs HH, Van Hout C. Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance. Journal of Lipid Research. 2020;61(9):1271-86.

12. Bonanni L, Cutolo A, Dalla Vestra M. Novel Approaches for the treatment of familial hypercholesterolemia. Exp Clin Endocrinol Diabetes. 2016;124:583–7.

13. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489–99.

14. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500–9.

15. Shimizugawa T, Ono M, Shimamura M, et al. ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J Biol Chem. 2002;277:33742–8.

16. Shimamura M, Matsuda M, Yasumo H, et al. Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase. Arterioscler Thromb Vasc Biol. 2007;27:366–72.

17. Gusarova V, Alexa CA, Wang Y, et al. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. J Lipid Res. 2015;56:1308–17.

18. Harada M, Yamakawa T, Kashiwagi R, Ohira A, Sugiyama M, Sugiura Y, Kondo Y, Terauchi Y. Association between ANGPTL3, 4, and 8 and lipid and glucose metabolism markers in patients with diabetes. PLoS One. 2021;16(7):e0255147.

19. Bagias C, Xiarchou A, Bargiota A, Tiga S. Familial Partial Lipodystrophy (FPLD): Recent Insights. Diabetes Metab Syndr Obes. 2020;13:1531–444.

20. Oral EA, Gorden P, Cochran E, Araujo-Vilar D, Savage DB, Long A, Fine G, Salinardi T, Brown RJ. Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy. Endocrine. 2019;64:500–11.

21. Polyzos SA, Perakakis N, Mantzoros CS. Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement. Metabolism. 2019;96:66–82.

22. Akinci B, Oral EA, Neidert A, Rus D, Cheng WY, Thompson-Leduc P, Cheung HC, Bradt P, Foss de Freitas MC, Montenegro RM, et al. Comorbidities and Survival in Patients With Lipodystrophy: An International Chart Review Study. J Clin Endocrinol Metab. 2019;104:5120–35.

© 2021 Rai; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle5.com/review-history/76608